^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BTG1 mutation

    i
    Other names: BTG1, BTG Anti-Proliferation Factor 1, APRO2, B-Cell Translocation Gene 1, Anti-Proliferative, B-Cell Translocation Gene 1 Protein, Protein BTG1
    Entrez ID:
    694
    over2years
    Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Diffuse Large B-cell Lymphoma. (PubMed, Hemasphere)
    Together, we demonstrate variable clonal B-cell dynamics in LPL/WM patients developing DLBCL, and the occurrence of clonally unrelated DLBCL in about one-quarter of LPL/WM patients. Moreover, we identified commonly mutated genes upon DLBCL transformation, which together with preserved mutations already present in LPL characterize the mutational landscape of DLBCL occurrences in LPL/WM patients.
    Journal
    |
    TP53 (Tumor protein P53) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CD79B (CD79b Molecule) • CARD11 (Caspase Recruitment Domain Family Member 11) • TNFAIP3 (TNF Alpha Induced Protein 3) • PIM1 (Pim-1 Proto-Oncogene) • BTG1 (BTG Anti-Proliferation Factor 1) • BTG2 (BTG Anti-Proliferation Factor 2)
    |
    TP53 mutation • MYD88 mutation • CXCR4 mutation • CD79B mutation • TNFAIP3 mutation • BTG1 mutation • CD79B mutation + TNFAIP3 mutation
    over2years
    Molecular classification of systemic diffuse large B-cell lymphoma in Korea (ECP 2023)
    The identification of specific mutations in each subgroup, which were largely consistent with previous studies, indicates that the LymphGen classifier may be valuable in individualized treatment approaches for DLBCL patients. Additionally, this study demonstrates that unclassified group ("Other") may potentially be established as a distinct subgroup.
    IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • CD79B (CD79b Molecule) • KMT2C (Lysine Methyltransferase 2C) • PIM1 (Pim-1 Proto-Oncogene) • IRF4 (Interferon regulatory factor 4) • SOCS1 (Suppressor Of Cytokine Signaling 1) • PRDM1 (PR/SET Domain 1) • BTG1 (BTG Anti-Proliferation Factor 1) • H1-4 (H1.4 Linker Histone, Cluster Member)
    |
    TP53 mutation • TET2 mutation • KMT2D mutation • EZH2 mutation • CD79B mutation • PIM1 mutation • BTG1 mutation • IRF4 mutation